KB001A-05, A Phase 2, Randomized, Double-blind, Placebo-controlled, Repeat-dose Study of KB001 A in Subjects with Cystic Fibrosis Infected with Pseudomonas aeruginosa
|Effective start/end date||11/30/12 → 6/30/15|
- KaloBios Pharmaceuticals, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.